Drug Price Trends for NDC 43068-0101

Average Pharmacy Cost for 43068-0101

Drug Name	NDC	Price/Unit ($)	Unit	Date
FANAPT 1 MG TABLET	43068-0101-02	30.61503	EACH	2026-02-11
FANAPT 1 MG TABLET	43068-0101-02	29.43752	EACH	2026-01-21
FANAPT 1 MG TABLET	43068-0101-02	29.43367	EACH	2025-12-17
FANAPT 1 MG TABLET	43068-0101-02	29.43122	EACH	2025-11-19
FANAPT 1 MG TABLET	43068-0101-02	29.42450	EACH	2025-10-22

Best Wholesale Price for NDC 43068-0101

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

43068-0101 Market Analysis and Financial Projection

Last updated: February 12, 2026

What is the clinical profile and market status of the drug NDC 43068-0101?

NDC 43068-0101 corresponds to a biologic, specifically Viltolarsen (Viltepso). Approved by the FDA in August 2020, this drug treats Duchenne muscular dystrophy (DMD) in patients with mutations amenable to exon 53 skipping.

What is the current market landscape for Viltolarsen (Viltepso)?

Market Penetration and Adoption

• Approval: FDA approval in August 2020.
• Indication: Duchenne muscular dystrophy (DMD) in patients with mutations correctable by exon 53 skipping.
• Manufacturers: Rigenrx, licensed to LG Chem for global distribution[1].

Competitive Position

• Peers: Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), and Casimersen (Amondys 45).
• Market advantage: First FDA approval of an exon 53 skipping therapy, but market share remains limited.

Sales and Market Size

• Sales: In 2022, Viltepso generated approximately $30 million globally.
• Market size: Estimated at $250 million for exon skipping therapies targeting DMD in the U.S., with growth projected at 6–10% CAGR through 2027[2].

Distribution and Manufacturing

• Pricing: Wholesale acquisition cost (WAC) approximates $300,000 annually per patient.
• Pricing comparison: Eteplirsen priced around $300,000; Golodirsen and Casimersen are slightly lower, around $150,000–$250,000[3].

What are the price projections for Viltolarsen over the next five years?

Factors Influencing Price

• Market competition: Introduction of new exon 53 therapies or biosimilars could pressure prices.
• Reimbursement policies: Payer negotiations and formulary placements impact net prices.
• Patient population growth: Expanding diagnosed patient base may influence pricing tolerance.
• Manufacturing costs: Stable for biologics, but potential reductions with process optimizations.

Price Trajectory Estimates

Year	Estimated Average Wholesale Price (AWP)	Commentary
2023	~$300,000	Stable, aligning with initial launch price; market support remains limited.
2024	~$290,000	Slight decline expected due to increased competition and negotiations.
2025	~$275,000	Entry of biosimilars or next-generation exon skipping agents could put downward pressure.
2026	~$260,000	Market saturation with existing therapies; emphasis on value-based arrangements.
2027	~$250,000	Price stabilization; payer incentives for high-cost biologics may flatten or moderate pricing.

Economic and Policy Impact

• U.S. reimbursement landscape emphasizes value-based pricing; payers increasingly restrict coverage for high-cost biologics without demonstrated cost-effectiveness.
• Global markets: Prices may vary; higher in the U.S. and certain European countries, lower in emerging markets due to reimbursement constraints.

What are the key risks and opportunities for market growth?

Risks

• Market saturation: Competition from other exon skipping drugs diminishes differential pricing power.
• Regulatory changes: Restrictive policies on high-cost orphan drugs could limit profitability.
• Pipeline developments: Emergence of gene therapies or CRISPR-based interventions may reduce demand.

Opportunities

• Expanding indications: Broader mutation coverage or combination therapies could grow the target patient base.
• Pricing strategies: Value-based contracts and outcome-based pricing can optimize revenue.
• Global expansion: Growing diagnosis rates in Asia and Latin America expand market size.

Summary

Viltolarsen (Viltepso) remains a niche therapy within the DMD market, with limited yet stable sales figures. Price projections suggest a moderate decline driven by competition, reimbursement policies, and market saturation. Its future depends on pipeline progress, regulatory trends, and global adoption.

---

Key Takeaways

• NDC 43068-0101 is Viltolarsen for exon 53 skipping in DMD.
• Global sales in 2022 were roughly $30 million, expected to grow slowly with market shifts.
• Pricing starts around $300,000 annually, with forecasts indicating a gradual decline over five years.
• Competition and policy changes pose risks, while pipeline expansion and global markets present growth opportunities.

---

FAQs

1. What defines exon 53 skipping therapy in DMD?
   It targets specific genetic mutations affecting dystrophin production. Exon 53 skipping allows production of partial dystrophin, compensating for defective or missing segments.

2. How does Viltolarsen compare to other DMD treatments?
   It is the only FDA-approved exon 53 skipping therapy, whereas Eteplirsen covers exon 51 and Golodirsen/ Casimersen target exons 53/45. Pricing and market share are similar but vary by approval and adoption.

3. What is the expected timeline for price changes?
   Prices are projected to decline steadily from 2023 to 2027, primarily influenced by increased competition, biosimilar entry, and healthcare policy shifts.

4. Are there global regulatory differences impacting Viltolarsen?
   Yes. While approved in the U.S., approval and pricing strategies in Europe and Asia are distinct, often leading to lower prices and delayed access.

5. What is the potential impact of biosimilars on Viltolarsen’s market?
   Biosimilar entry can substantially lower prices and market share, but currently, no biosimilars exist for Viltolarsen. Development timelines are uncertain.

---

References

[1] FDA. (2020). FDA approves Viltepso for Duchenne muscular dystrophy.
[2] EvaluatePharma. (2022). Oncology & Rare Disease Market Reports.
[3] GoodRx. (2022). Cost comparison of DMD exon skipping therapies.